Rare bone disease patients tracked in Long-Term drug safety study

NCT ID NCT04783428

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times

Summary

This study follows 23 people with tumor-induced osteomalacia (TIO), a rare condition that causes weak bones due to tumors. Researchers are checking the long-term safety and effectiveness of the drug burosumab, which helps control phosphate levels. Participants continue their prescribed treatment while doctors monitor their health, tumor changes, and quality of life over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR-INDUCED OSTEOMALACIA (TIO) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas

    Buenos Aires, Argentina

  • Indiana University

    Bloomington, Indiana, 47405, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37235, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.